Debasish Roychowdhury, MD is a medical oncologist with over 15 years of comprehensive pharmaceutical industry and senior management experience and over 14 years of patient care, academic research and teaching experience. Debasish is a leader in the pharmaceutical industry across multiple functional and cross-functional areas, regions and matrices, including – all stages of R&D, regulatory, commercial operations and medical affairs, market access, business development and alliance management. Debasish was involved in nine new drug approvals in US and EU and other markets and numerous supplemental approvals.
Debasish Roychowdhury is currently President of Nirvan Consultants, LLC and advises biotechnology companies and institutions. He was one of the founding members of the Seragon Clinical and Scientific Advisory Board and was the company’s Chief Medical Officer where he played a key role in the development and advancement of Seragon’s selective estrogen receptor degrader (SERD) platform for breast cancer and other hormone-driven cancers till the company was acquired by Roche in August 2014.
Prior to Seragon, Debasish was the Senior Vice President and Head of the Global Oncology Division at Sanofi till November 2013. Prior to that, he served as the Vice President for Clinical Development at GlaxoSmithKline and directed the Oncology global regulatory group at Eli Lilly and Company. Prior to his role in industry, he served as faculty member at the University of Cincinnati. He trained at the All India Institute of Medical Sciences and University of California, San Francisco. He is a member of the Board of Directors for Lytix Biopharma AS.